Roivant: IMVT-1402 600 mg Phase 1 data shows best-in-class potential; 74% IgG reduction

Roivant Sciences Ltd.

Four weekly SC doses of 600 mg IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% reduction.
Serum albumin and LDL-C at Day 29 showed no significant change from baseline (p>0.05), indicating placebo-like safety.
Steady-state IgG reduction expected to reach ~80% with continued weekly dosing, matching batoclimab's timing of 6-8 weeks.
Treatment was well tolerated with only mild or moderate adverse events observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.